Willemse Jorke, van der Laan Luc J W, de Jonge Jeroen, Verstegen Monique M A
Department of Surgery, Erasmus MC Transplant Institute, University Medical Center, 3015 CN Rotterdam, The Netherlands.
Bioengineering (Basel). 2022 Mar 7;9(3):110. doi: 10.3390/bioengineering9030110.
Organoid technology holds great promise for regenerative medicine. Recent studies show feasibility for bile duct tissue repair in humans by successfully transplanting cholangiocyte organoids in liver grafts during perfusion. Large-scale expansion of cholangiocytes is essential for extending these regenerative medicine applications. Human cholangiocyte organoids have a high and stable proliferation capacity, making them an attractive source of cholangiocytes. Commercially available basement membrane extract (BME) is used to expand the organoids. BME allows the cells to self-organize into 3D structures and stimulates cell proliferation. However, the use of BME is limiting the clinical applications of the organoids. There is a need for alternative tissue-specific and clinically relevant culture substrates capable of supporting organoid proliferation. Hydrogels prepared from decellularized and solubilized native livers are an attractive alternative for BME. These hydrogels can be used for the culture and expansion of cholangiocyte organoids in a clinically relevant manner. Moreover, the liver-derived hydrogels retain tissue-specific aspects of the extracellular microenvironment. They are composed of a complex mixture of bioactive and biodegradable extracellular matrix (ECM) components and can support the growth of various hepatobiliary cells. In this review, we provide an overview of the clinical potential of native liver ECM-based hydrogels for applications with human cholangiocyte organoids. We discuss the current limitations of BME for the clinical applications of organoids and how native ECM hydrogels can potentially overcome these problems in an effort to unlock the full regenerative clinical potential of the organoids.
类器官技术在再生医学领域具有巨大潜力。最近的研究表明,通过在灌注过程中将胆管细胞类器官成功移植到肝脏移植物中,人类胆管组织修复具有可行性。胆管细胞的大规模扩增对于扩展这些再生医学应用至关重要。人类胆管细胞类器官具有高且稳定的增殖能力,使其成为胆管细胞的一个有吸引力的来源。市售的基底膜提取物(BME)用于扩增类器官。BME使细胞能够自组织成三维结构并刺激细胞增殖。然而,BME的使用限制了类器官的临床应用。需要能够支持类器官增殖的替代组织特异性和临床相关的培养底物。由脱细胞和溶解的天然肝脏制备的水凝胶是BME的一个有吸引力的替代品。这些水凝胶可用于以临床相关的方式培养和扩增胆管细胞类器官。此外,肝脏衍生的水凝胶保留了细胞外微环境的组织特异性方面。它们由生物活性和可生物降解的细胞外基质(ECM)成分的复杂混合物组成,并且可以支持各种肝胆细胞的生长。在这篇综述中,我们概述了基于天然肝脏ECM的水凝胶在人类胆管细胞类器官应用中的临床潜力。我们讨论了BME在类器官临床应用中的当前局限性,以及天然ECM水凝胶如何有可能克服这些问题,以努力释放类器官的全部再生临床潜力。